Actionable Decisions & Strategic Risk in Covalent Drug Discovery
9:00 am - Thursday 22nd October 2026
- Interrogating covalent and reversible-covalent hits in the absence of a clear hypothesis to identify the truly functional system and define allosteric modulation strategies
- Uncovering mechanism beyond inhibition by revealing PPI disruption as the primary driver of efficacy through target engagement and mass spec validation
- Applying context dependent reversibility and chemical risk assessments to make decisive go/no go calls, advancing one program through preclinical safety while strategically discontinuing another
